Ignite Creation Date:
2024-05-06 @ 10:12 AM
Last Modification Date:
2024-10-26 @ 12:26 PM
Study NCT ID:
NCT03196921
Status:
WITHDRAWN
Last Update Posted:
2019-03-08
First Post:
2017-06-19
Brief Title:
Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal Infection
Sponsor:
Matinas BioPharma Nanotechnologies Inc
Organization:
Matinas BioPharma Nanotechnologies Inc
Study Overview
Official Title:
A Prospective Cohort to Evaluate the Efficacy and Safety of Oral Encochleated Amphotericin B CAMBMAT2203 for the Treatment of Cryptococcal Infection
Status:
WITHDRAWN
Status Verified Date:
2019-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Protocol redundancy
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ORACLE
Brief Summary:
This will be an open label phase III prospective cohort study to determine the efficacy and safety of CAMB for the treatment and prevention of cryptococcal infection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None